NO964713D0 - DNA-basert vaksinering av fisk ved immersjon - Google Patents

DNA-basert vaksinering av fisk ved immersjon

Info

Publication number
NO964713D0
NO964713D0 NO964713A NO964713A NO964713D0 NO 964713 D0 NO964713 D0 NO 964713D0 NO 964713 A NO964713 A NO 964713A NO 964713 A NO964713 A NO 964713A NO 964713 D0 NO964713 D0 NO 964713D0
Authority
NO
Norway
Prior art keywords
fish
immersion
dna
based vaccination
vaccination
Prior art date
Application number
NO964713A
Other languages
English (en)
Other versions
NO325343B1 (no
NO964713L (no
Inventor
Heather L Davis
Original Assignee
Loeb Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loeb Research Inst filed Critical Loeb Research Inst
Publication of NO964713D0 publication Critical patent/NO964713D0/no
Publication of NO964713L publication Critical patent/NO964713L/no
Publication of NO325343B1 publication Critical patent/NO325343B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/817—Viral vaccine for fish

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19964713A 1995-11-07 1996-11-07 DNA-basert vaksinering av fisk ved immersjon NO325343B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US629095P 1995-11-07 1995-11-07
US08/740,805 US5780448A (en) 1995-11-07 1996-11-04 DNA-based vaccination of fish

Publications (3)

Publication Number Publication Date
NO964713D0 true NO964713D0 (no) 1996-11-07
NO964713L NO964713L (no) 1997-05-09
NO325343B1 NO325343B1 (no) 2008-04-07

Family

ID=26675437

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964713A NO325343B1 (no) 1995-11-07 1996-11-07 DNA-basert vaksinering av fisk ved immersjon

Country Status (6)

Country Link
US (2) US5780448A (no)
EP (2) EP0773295B1 (no)
JP (1) JPH09285291A (no)
CA (1) CA2189831C (no)
DK (1) DK0773295T3 (no)
NO (1) NO325343B1 (no)

Families Citing this family (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
PT839913E (pt) * 1996-11-04 2006-09-29 Ottawa Health Research Inst Metodo de expressao de polipeptidos em peixe por imerssao numa solucao de adn plasmidico
EP1003556B1 (en) * 1996-11-04 2006-03-01 Qiagen GmbH Cationic reagents for transfection
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP0973865A2 (en) * 1997-04-11 2000-01-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
US6010705A (en) * 1997-04-11 2000-01-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
ATE370740T1 (de) * 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6432641B1 (en) 1997-12-16 2002-08-13 University Of Saskatchewan Technologies Inc. Conductive metal-containing nucleic acids
US6153202A (en) * 1998-03-06 2000-11-28 The United States Of America As Represented By The Secretary Of Agriculture In ovo methods for utilizing live Edwardsiella ictaluri against enteric septicemia in channel catfish
ATE356630T1 (de) * 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
AU3884199A (en) * 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
DE69927495T2 (de) * 1998-05-14 2006-07-06 Coley Pharmaceutical Group, Inc., Wellesley Verfahren zur regulieren der hämatopoese mit hilfe von cpg-oligonukleotiden
DK1077722T3 (da) * 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6881561B1 (en) * 1998-05-27 2005-04-19 Cheil Jedang Corporation Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6462027B2 (en) 1998-07-06 2002-10-08 University Of Georgia Research Foundation, Inc. Delivery of nucleic acid into aquatic animals
US20070071776A1 (en) * 1998-09-28 2007-03-29 National University Of Singapore Recombinant Vaccine Against Fish Infectious Diseases
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
US7026156B1 (en) 1999-02-04 2006-04-11 The University Of Georgia Research Foundation, Inc. Diagnostic and protective antigen gene sequences of ichthyophthirius
US7326568B2 (en) * 1999-02-04 2008-02-05 University Of Georgia Research Foundation, Inc. Recombinant expression of heterologous nucleic acids in protozoa
US6846481B1 (en) 1999-02-04 2005-01-25 University Of Georgia Research Foundation, Inc. Recombinant expression of heterologous nucleic acids in protozoa
AU2756300A (en) * 1999-02-04 2000-08-25 University Of Georgia Research Foundation, Inc., The Recombinant expression of heterologous nucleic acids in protozoa
ATE464907T1 (de) * 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
CA2299119C (en) 1999-02-23 2013-02-05 Qiagen Gmbh A method of stabilizing and/or isolating nucleic acids
WO2000063692A1 (en) * 1999-04-15 2000-10-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
NO311648B1 (no) * 1999-05-31 2001-12-27 Genomar Asa DNA-sekvenser som kan benyttes til vaksine, forebyggende helsearbeid på fisk og akvatiske organismer og ellers innenbiomedisin, vektor, vaksine mot ILA-virus samt diagnostisk sett
CA2372994C (en) * 1999-06-04 2010-03-23 Alza Corporation Implantable gel compositions and method of manufacture
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20040109874A1 (en) * 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
JP2003535577A (ja) * 2000-01-28 2003-12-02 トーマス・ジェファーソン・ユニバーシティー 免疫不全ウイルス用生ウイルスワクチンとしての組換えラブドウイルス
CA2405424A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
US20030022359A1 (en) 2000-06-20 2003-01-30 Sayre Richard T. Transgenic algae for delivering antigens to an animal
ATE440618T1 (de) 2000-06-22 2009-09-15 Univ Iowa Res Found Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
US7083858B1 (en) 2000-07-26 2006-08-01 Worthen Industries, Inc. Thermally activated adhesive films for the collation of wire staples
KR20020035457A (ko) * 2000-11-04 2002-05-11 정웅 한국형 전염성 조혈기 괴사 바이러스의 신규 지 및 엠1유전자 및 이를 이용한 어류 백신
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
ES2380007T3 (es) * 2001-04-06 2012-05-07 The University Of Chicago Inducción por agentes quimioterapéuticos de la actividad del promotor Egr-1 en la terapia génica
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US7452705B2 (en) 2001-05-22 2008-11-18 The University Of Chicago N4 virion single-stranded DNA dependent RNA polymerase
CA2447089A1 (en) * 2001-05-24 2002-11-28 University Of Saskatchewan Technologies Inc. Nucleic acid circuit elements and methods
US6936256B2 (en) * 2001-08-10 2005-08-30 University Of Maryland Biotechnology Institute Sub-unit vaccine for infectious pancreatic necrosis virus
EA007232B1 (ru) 2001-08-17 2006-08-25 Коли Фармасьютикал Гмбх Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
JP4863341B2 (ja) * 2001-09-06 2012-01-25 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ヒラメラブドウイルス感染魚類用ｄｎａワクチン
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
EP1425040A2 (en) * 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002348417B9 (en) * 2001-10-26 2010-02-04 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
EP1441763A2 (en) * 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
CA2469310C (en) 2001-12-11 2013-01-29 Advisys, Inc. Plasmid mediated supplementation for treating chronically ill subjects
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
EP2213737B1 (en) 2002-02-01 2012-11-07 Life Technologies Corporation Double-stranded oligonucleotides
US20030158103A1 (en) * 2002-02-19 2003-08-21 Aqua Bounty Farms, Inc. Prevention of viral and bacterial disease in shrimp
US20040147467A1 (en) * 2002-03-29 2004-07-29 Clouthier Sharon C. Nucleic acids encoding isav polypeptides
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
KR100456681B1 (ko) * 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
DE60336023D1 (de) 2002-07-15 2011-03-24 Univ Texas Screening kombinatorischer proteinbibliotheken mittels periplasmatischer expression
ES2444699T3 (es) 2002-08-12 2014-02-26 Jennerex, Inc. Virus vaccinia para uso en el tratamiento del cáncer
US7501128B2 (en) * 2002-09-17 2009-03-10 Novartis Animal Health Us, Inc. IHNV G protein for immune stimulation
EP1556077A2 (en) 2002-10-29 2005-07-27 Coley Pharmaceutical Group, Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
TWI350310B (en) 2002-12-13 2011-10-11 Novartis Ag Immunization of fish with plant-expressed recombinant proteins
IL153775A0 (en) * 2003-01-01 2003-07-31 Yissum Res Dev Co Immunizing fish against viral infection
EP1606398A1 (en) * 2003-03-26 2005-12-21 Cytos Biotechnology AG Melan-a peptide analogue-virus-like-particle conjugates
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
AU2004238139B2 (en) 2003-05-15 2009-12-03 Mitsui Dm Sugar Co.,Ltd. Immunostimulating Agents
US7049076B2 (en) 2003-07-09 2006-05-23 Sentigen Biosciences, Inc. Method for assaying protein—protein interaction
US20070224615A1 (en) * 2003-07-09 2007-09-27 Invitrogen Corporation Methods for assaying protein-protein interactions
GB0317733D0 (en) * 2003-07-29 2003-09-03 Novartis Ag Organic compounds
WO2005030259A2 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US7204993B2 (en) * 2004-03-18 2007-04-17 The United States Of America As Represented By The Secretary Of Agriculture Streptococcus agalactiae vaccine
US20070287150A1 (en) * 2004-03-18 2007-12-13 Rohrschneider Larry R Methods And Compositions Involving S-Ship Promoter Regions
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
TR200606983T1 (tr) * 2004-05-19 2007-02-21 Agence Fran�Aise De S�Curit� Sanitaire Des Aliments (Afssa) Nodavirüs-VLP bağışıklaştırma bileşimi
WO2006017279A2 (en) * 2004-07-12 2006-02-16 Board Of Regents, The University Of Texas System Methods and compositions related to identifying protein-protein interactions
EP1781325A2 (en) * 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US7334538B1 (en) * 2004-07-27 2008-02-26 Aquascience Research Group, Inc. Topical medicants for aquatic animals
ES2247942B1 (es) * 2004-08-27 2006-10-01 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) Construccion genica, vector y vacuna adn para la vacunacion de animales acuaticos.
EP2302051B1 (en) 2004-11-12 2015-01-07 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
KR100701672B1 (ko) * 2004-12-10 2007-04-03 대한민국 한국형 돌돔 이리도바이러스의 유전자 및 이를 이용한 백신
KR20070120970A (ko) * 2005-02-23 2007-12-26 유에이비 리서치 파운데이션 알킬-글리코시드로 증진된 예방접종
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CN100370023C (zh) * 2005-11-17 2008-02-20 中国海洋大学 利用大菱鲆鳍细胞系繁殖大菱鲆出血性败血症病毒的方法
WO2007080203A1 (es) * 2006-01-11 2007-07-19 Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) Construcción genica, vector y vacuna de adn para la vacunación de animales acuáticos
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
JP5239023B2 (ja) 2006-04-13 2013-07-17 国立大学法人東京海洋大学 コイヘルペスウイルス（ｋｈｖ）病用ｄｎａワクチン
WO2008014484A1 (en) 2006-07-27 2008-01-31 University Of Maryland, Baltimore Cellular receptor for antiproliferative factor
JP5606067B2 (ja) * 2006-09-15 2014-10-15 オタワ ホスピタル リサーチ インスティテュート 腫瘍崩壊性ラブドウイルス
CN101617039A (zh) 2006-10-20 2009-12-30 代表亚利桑那大学的亚利桑那校董会 经修饰的蓝细菌
CA2671264C (en) 2006-11-30 2015-11-24 Research Development Foundation Improved immunoglobulin libraries
JP2010514412A (ja) * 2006-12-22 2010-05-06 ソリューシオネス バイオテクノロジカス イノヴァシオン リミターダ Ｄｎａ魚ワクチン
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
CA2685675C (en) 2007-05-01 2016-02-16 Research Development Foundation Immunoglobulin fc libraries
US20100317084A1 (en) * 2007-05-10 2010-12-16 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
WO2009025888A2 (en) * 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
CN105367656A (zh) 2007-08-31 2016-03-02 芝加哥大学 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物
GB0717911D0 (en) 2007-09-14 2007-10-24 Univ Stirling Vaccine
WO2009046451A1 (en) * 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting a protective immune response against c. perfringens
MX2010007530A (es) 2008-01-10 2010-11-10 Res Dev Foundation Vacunas y diagnosticos para ehrlichiosis.
ES2617598T3 (es) 2008-01-25 2017-06-19 Multivir Inc. Biomarcadores de P53
CA2718904C (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
GB0808780D0 (en) * 2008-05-15 2008-06-18 Big Dna Ltd Fish vaccines
EP3112456A1 (en) 2008-06-04 2017-01-04 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
US9175268B2 (en) 2008-08-12 2015-11-03 Cellular Dynamics International, Inc. Methods for the production of iPS cells
AU2009282625A1 (en) 2008-08-18 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derivatives of APF and methods of use
JP2012504660A (ja) 2008-10-06 2012-02-23 ユニバーシティ オブ シカゴ 細菌ｅａｐ、ｅｍｐおよび／またはａｄｓａタンパク質に関連する組成物および方法
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
CN102317442B (zh) 2008-12-17 2014-08-13 斯克里普斯研究所 干细胞的产生和保持
WO2010084488A1 (en) 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
US20100183523A1 (en) 2009-01-22 2010-07-22 Wagner Richard E Dental composition and method
US9567379B2 (en) 2009-04-03 2017-02-14 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
ES2568938T3 (es) 2009-04-28 2016-05-05 Vanderbilt University Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales
GB2483595B (en) 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
CA2952805C (en) 2009-06-05 2021-06-01 Cellular Dynamics International, Inc. Reprogramming t cells and hematopoietic cells
CA2772298A1 (en) 2009-08-26 2011-03-03 Research Development Foundation Methods for creating antibody libraries
AU2010291901C1 (en) 2009-09-14 2016-03-03 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus combination cancer therapy
EP2488547B1 (en) 2009-10-15 2017-12-06 University Court of the University of Edinburgh Staphylococcal antigens
RU2012117719A (ru) 2009-10-16 2013-11-27 Зе Скрипс Ресеч Инститьют Индукция плюрипотентных клеток
CA2836117C (en) 2009-12-10 2017-08-15 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
US8889121B2 (en) 2010-01-22 2014-11-18 The Arizona Board Of Regents For An On Behalf Of Arizona State University Bacterium comprising a regulated rfaH nucleic acid
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
JP5933459B2 (ja) 2010-02-25 2016-06-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｒａｆ阻害剤に対する耐性を付与するｂｒａｆ突然変異
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
US9249195B2 (en) 2010-04-07 2016-02-02 Vanderbilt University Reovirus vaccines and methods of use therefor
US8785385B2 (en) 2010-04-19 2014-07-22 Research Development Foundation RTEF-1 variants and uses thereof
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
MX342966B (es) 2010-06-09 2016-10-19 Dana Farber Cancer Inst Inc Una mutacion mek1 que confiere resistencia a inhibidores raf y mek.
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
EP3382008A1 (en) 2010-06-15 2018-10-03 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
US20110312001A1 (en) 2010-06-15 2011-12-22 Emile Nuwaysir Compendium of ready-built stem cell models for interrogation of biological response
SG186290A1 (en) 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
NZ605420A (en) 2010-07-06 2015-02-27 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US8785192B2 (en) 2010-07-07 2014-07-22 Cellular Dynamics International, Inc. Endothelial cell production by programming
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
FR2964569B1 (fr) 2010-09-10 2012-10-19 Ct De Cooperation Internationale En Rech Agronomique Pour Le Dev Cirad Nouveaux liposomes de vaccination genique
EP3536337A1 (en) 2010-09-22 2019-09-11 The Regents of the University of Colorado, a body corporate Therapeutic applications of smad7
WO2012044979A2 (en) 2010-10-01 2012-04-05 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Manipulation of stem cell function by p53 isoforms
KR101975688B1 (ko) 2010-12-22 2019-05-07 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
CN103429258B (zh) 2011-01-04 2016-03-09 新罗杰公司 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
CA2826467C (en) 2011-02-07 2019-11-12 Research Development Foundation Engineered immunoglobulin fc polypeptides
EP2673358B1 (en) 2011-02-08 2019-01-09 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
US9085631B2 (en) 2011-04-08 2015-07-21 Nov Vac APS Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
ES2931180T3 (es) 2011-05-19 2022-12-27 Fund Publica Andaluza Progreso Y Salud Sistema de tipo Tet-on lentivírico de promotor dual muy inducible
ES2627529T3 (es) 2011-06-08 2017-07-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Composiciones para tratamiento de glioblastoma
US20130040302A1 (en) 2011-07-11 2013-02-14 Thomas J. Burke Methods for cell reprogramming and genome engineering
JP6317670B2 (ja) 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
EP2753686A4 (en) * 2011-09-09 2015-06-03 Advanced Bionutrition Corp BIVALENT IPNV ISAV VACCINE USING A VIRUS LIKE PARTICLE PLATFORM AND USE METHOD THEREFOR
EP2766388A1 (en) 2011-10-12 2014-08-20 Møller, Niels Iversen Peptides derived from campylobacter jejuni and their use in vaccination
WO2013086514A1 (en) 2011-12-08 2013-06-13 Pentair Water Pool And Spa, Inc. Aquaculture pump system and method
ES2886147T3 (es) 2011-12-22 2021-12-16 Interna Tech B V MiARN para el tratamiento del cáncer de cabeza y de cuello
WO2013144579A1 (en) 2012-03-30 2013-10-03 Heriot-Watt University Use of flagellin as a vaccine
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
AU2013252888B2 (en) 2012-04-26 2018-06-14 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
EP2870238A4 (en) 2012-07-05 2016-03-09 Ohio State Innovation Foundation COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
CN104736169B (zh) * 2012-09-10 2018-04-17 国立大学法人东京海洋大学 海产鱼的类结节病用dna疫苗
WO2014046410A1 (ko) * 2012-09-20 2014-03-27 중앙대학교 산학협력단 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물
CA2887825A1 (en) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Engineered igg fc domains
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
RU2690352C2 (ru) 2013-02-20 2019-05-31 Регенерон Фармасютикалс, Инк. Генетическая модификация крыс
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
JP2016508726A (ja) 2013-02-22 2016-03-24 セルラー ダイナミクス インターナショナル， インコーポレイテッド 組み合わせた遺伝的および化学的操作によるフォワードプログラミングを介した肝細胞の産生
EP2961386B1 (en) 2013-02-28 2019-07-10 The General Hospital Corporation Mirna profiling compositions and methods of use
WO2014132137A2 (en) 2013-03-01 2014-09-04 Université De Genève Transgenic cell selection
US9422352B2 (en) 2013-03-08 2016-08-23 The Regents Of The University Of Colorado, A Body Corporate PTD-SMAD7 therapeutics
US9693538B2 (en) 2013-03-14 2017-07-04 Pentair Water Pool And Spa, Inc. Carbon dioxide control system for aquaculture
EP2967008A4 (en) 2013-03-15 2016-11-23 Pentair Water Pool & Spa Inc CONTROL SYSTEM OF SLAUGHTERED OXYGEN FOR AN AQUACULTURE
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
CA2923857A1 (en) 2013-09-09 2015-03-12 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
CA2929555A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
EP3065775B1 (en) 2013-11-08 2020-09-30 The Board of Regents of the University of Texas System Vh4 antibodies against gray matter neuron and astrocyte
JP6669650B2 (ja) * 2013-11-15 2020-03-18 ユニバーシティ オブ メリーランド，ボルチモア カウンティ 生殖能力のない魚及び卵生水生動物を作出する方法、ならびに卵及び胚内に化合物を送達する方法
WO2015082536A1 (en) 2013-12-03 2015-06-11 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
KR102448454B1 (ko) 2014-01-29 2022-09-28 다나-파버 캔서 인스티튜트 인크. Muc1-c/세포외 도메인 (muc1-c/ecd)에 대한 항체
WO2015123561A2 (en) 2014-02-14 2015-08-20 University Of Utah Research Foundation Methods and compositions for inhibiting retinopathy of prematurity
EP3110836A1 (en) 2014-02-25 2017-01-04 Research Development Foundation Sty peptides for inhibition of angiogenesis
ES2966757T3 (es) 2014-03-04 2024-04-24 Fate Therapeutics Inc Métodos de reprogramación mejorados y plataformas de cultivo celular
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
JP6581604B2 (ja) 2014-06-04 2019-09-25 イグジキュア, インコーポレーテッドExicure, Inc. 予防的または治療的適用のためのリポソーム球状核酸による免疫調節物質の多価送達
US20180363070A9 (en) 2014-08-12 2018-12-20 Univ Wayne State Systems and methods to detect stem cell stress and uses thereof
EP3777883A1 (en) 2014-11-13 2021-02-17 Evaxion Biotech ApS Peptides derived from acinetobacter baumannii and their use in vaccination
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10434162B2 (en) 2015-01-12 2019-10-08 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae
EP3250675A1 (en) 2015-01-28 2017-12-06 SABIC Global Technologies B.V. Methods and compositions for high-efficiency production of biofuel and/or biomass
WO2016130516A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
EP3259346A4 (en) 2015-02-20 2018-07-11 Baylor College of Medicine P63 inactivation for the treatment of heart failure
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP4116316A1 (en) 2015-07-04 2023-01-11 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
AU2016304343A1 (en) * 2015-07-31 2018-02-08 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
WO2017070337A1 (en) 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
IL258899B2 (en) 2015-10-30 2024-03-01 Univ California Methods for producing T cells from stem cells and immunotherapy methods using T cells
LT3370733T (lt) 2015-11-02 2021-10-25 Board Of Regents, The University Of Texas System Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
CN108884159A (zh) 2015-11-07 2018-11-23 茂体外尔公司 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
DK3373968T3 (da) 2015-11-09 2024-05-13 Childrens Hospital Philadelphia Glypican 2 som en tumormarkør og terapeutisk mål
EP3373852A4 (en) * 2015-11-13 2019-06-12 Applied Lifesciences and Systems, LLC AUTOMATIC SYSTEM AND METHOD FOR INJECTING A SUBSTANCE IN AN ANIMAL
CA3011920A1 (en) * 2016-02-02 2017-08-10 Benchmark Animal Health Limited Methods of producing viruses
EP3419654B1 (en) 2016-02-22 2022-04-27 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
EP3436049B1 (en) 2016-03-31 2022-01-12 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
WO2017216384A1 (en) 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination targeting ichthyophthirius multifiliis
WO2017220787A1 (en) 2016-06-24 2017-12-28 Evaxion Biotech Aps Vaccines against aearomonas salmonicida infection
EP3478325A4 (en) 2016-07-01 2020-01-15 Research Development Foundation REMOVAL OF CELL PROLIFERATIVE CELLS DERIVED FROM STEM CELLS
US11414464B2 (en) 2016-07-22 2022-08-16 Evaxion Biotech A/S Chimeric proteins for inducing immunity towards infection with S. aureus
WO2018035429A1 (en) 2016-08-18 2018-02-22 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
AU2017319702A1 (en) 2016-09-02 2019-04-11 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
CN110023491B (zh) 2016-10-05 2024-03-08 富士胶片细胞动力公司 多能干细胞定向分化为hla纯合免疫细胞的方法
JP7248571B2 (ja) 2016-10-05 2023-03-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド ＭｅＣＰ２が破壊された誘導多能性幹細胞からの成熟系列の生成
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
US11718648B2 (en) 2017-01-05 2023-08-08 Evaxion Biotech A/S Vaccines targeting Pseudomonas aeruginosa
EP4083063A3 (en) 2017-04-18 2023-01-04 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
CN107099496B (zh) * 2017-04-25 2021-04-13 中国农业科学院哈尔滨兽医研究所 融合表达鸡传染性法氏囊病毒vp2蛋白和沙门菌属外膜蛋白的重组乳酸菌菌株及其用途
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2019086603A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
WO2019099493A1 (en) 2017-11-14 2019-05-23 Henry Ford Health System Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
WO2019110664A1 (en) 2017-12-06 2019-06-13 Intervet International B.V. Use of a non-structural protein from prv to protect against heart and skeletal muscle inflammation
JP2021509815A (ja) 2018-01-05 2021-04-08 オタワ ホスピタル リサーチ インスティチュート 改変ワクシニアベクター
WO2019145399A1 (en) 2018-01-24 2019-08-01 Evaxion Biotech Aps Vaccines for prophylaxis of s. aureus infections
JP2021518408A (ja) 2018-03-19 2021-08-02 マルチビア インコーポレイテッド 癌治療のための、癌抑制遺伝子治療法及びｃｄ１２２／ｃｄ１３２アゴニストを含む、方法及び組成物
WO2019186274A2 (en) 2018-03-30 2019-10-03 University Of Geneva Micro rna expression constructs and uses thereof
RU2702716C2 (ru) * 2018-04-03 2019-10-09 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Рекомбинантная плазмида pHis6-flagG-protE, обеспечивающая синтез рекомбинантного химерного белка, включающего эпитопы гликопротеина Е вируса клещевого энцефалита и флагеллин G S.typhii и используемого в качестве основы для вакцины против вируса клещевого энцефалита
CA3111076A1 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
US20220000932A1 (en) 2018-09-28 2022-01-06 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
US20220111031A1 (en) 2018-10-22 2022-04-14 Evaxion Biotech Aps Vaccines targeting M. catharrhalis
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
US20220143168A1 (en) 2019-02-27 2022-05-12 Evaxion Biotech A/S Vaccines targeting H. influenzae
SG10201905939WA (en) 2019-06-26 2021-01-28 Cell Mogrify Australia Pty Ltd Cell culture methods and compositions
EP3997226A1 (en) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
EP3999546A1 (en) 2019-07-19 2022-05-25 The Children's Hospital of Philadelphia Chimeric antigen receptors containing glypican 2 binding domains
TW202128160A (zh) 2019-10-18 2021-08-01 美國加利福尼亞大學董事會 用於治療病原性血管病症之方法及組合物
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021140123A1 (en) 2020-01-06 2021-07-15 Evaxion Biotech Aps Vaccines targeting neisseria gonorrhoeae
CA3173567A1 (en) 2020-03-02 2021-09-10 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed micrornas
US20230211023A1 (en) 2020-03-25 2023-07-06 Erasmus University Medical Center Rotterdam Reporter system for radionuclide imaging
KR20230025804A (ko) 2020-05-27 2023-02-23 안티온 바이오사이언시즈 에스에이 Car t 세포를 관심 항원에 대해 재지시하기 위한 어댑터 분자
CA3180561A1 (en) 2020-05-29 2021-12-02 Andrew DIAS Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
EP4157294A1 (en) 2020-05-29 2023-04-05 FUJIFILM Cellular Dynamics, Inc. Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
EP4291216A1 (en) 2021-02-09 2023-12-20 University of Houston System Oncolytic virus for systemic delivery and enhanced anti-tumor activities
WO2022175815A1 (en) 2021-02-19 2022-08-25 Pfizer Inc. Methods of protecting rna
AU2022270611A1 (en) 2021-05-03 2023-10-12 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
WO2022235869A1 (en) 2021-05-07 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature hepatocytes
CN117881777A (zh) 2021-05-26 2024-04-12 富士胶片细胞动力公司 防止多能干细胞中基因快速沉默的方法
AU2022307747A1 (en) 2021-07-05 2024-01-25 Evaxion Biotech A/S Vaccines targeting neisseria gonorrhoeae
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
US20230295661A1 (en) 2022-03-16 2023-09-21 University Of Houston System Persistent hsv gene delivery system
GB202205265D0 (en) 2022-04-11 2022-05-25 Mogrify Ltd Cell conversion
WO2023213393A1 (en) 2022-05-04 2023-11-09 Evaxion Biotech A/S Staphylococcal protein variants and truncates
GB202206507D0 (en) 2022-05-04 2022-06-15 Antion Biosciences Sa Expression construct
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009259A (en) * 1975-10-03 1977-02-22 Wildlife Vaccines, Inc. Immersion method for treating aquatic animals
IL74289A (en) * 1985-02-10 1989-02-28 Israel State Vaccine system comprising a live-non-virulent vaccine and an adjuvant
US5354555A (en) * 1985-04-10 1994-10-11 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Vaccine to control the viral infection of fish
US5165925A (en) * 1989-05-02 1992-11-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Vaccine for immunizing fish against infectious pancreatic necrosis virus
US5076208A (en) * 1990-09-14 1991-12-31 Massachusetts Institute Of Technology Ultrasound-mediated administration of compounds into aquatic animals
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
CA2106315C (en) * 1991-03-15 2005-09-13 Choy L. Hew Gene construct for production of transgenic fish
IT1256575B (it) * 1992-12-10 1995-12-11 Cesalpino Andrea Fond Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.
EP0702516A4 (en) * 1993-06-01 1998-04-22 Life Technologies Inc GENETIC IMMUNIZATION WITH CATIONIC LIPIDS
FR2719316B1 (fr) * 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.

Also Published As

Publication number Publication date
US6180614B1 (en) 2001-01-30
CA2189831C (en) 2006-01-10
NO325343B1 (no) 2008-04-07
US5780448A (en) 1998-07-14
EP0773295A3 (en) 1999-06-16
EP1538210A2 (en) 2005-06-08
DK0773295T3 (da) 2006-12-27
EP0773295B1 (en) 2006-06-21
EP0773295A2 (en) 1997-05-14
NO964713L (no) 1997-05-09
CA2189831A1 (en) 1997-05-08
EP1538210A3 (en) 2006-02-01
JPH09285291A (ja) 1997-11-04

Similar Documents

Publication Publication Date Title
NO964713L (no) DNA-basert vaksinering av fisk ved immersjon
DE69608448T2 (de) Reduktion des biobewuchses
DE69605509D1 (de) Formenlose Herstellung von Metallkörper
BR9609797A (pt) Inibição de expressão de gene
NO20002076L (no) Blandinger inneholdende nyttige bestanddeler avledet fra fisk og skalldyr, samt fremgangsmÕte ved fremstilling derav
BR9609726A (pt) Inibição de expressão de gene
NO974229L (no) Fiskeagn
NO20013126D0 (no) Fremgangsmåte for slakting av fisk
DE69513313T2 (de) Verfahren zur Herstellung von Nukleinsäurebasenderivaten
NO982503D0 (no) FremgangsmÕte ved fremstilling av dioksoazabicykloheksaner
NO940753L (no) Fremgangsmåte ved lagring av fisk
NO963629D0 (no) Fremgangsmåte ved frysing av fisk
KR970003835U (ko) 수산물 양식용 원줄의 인양장치
NO971328D0 (no) Fremgangsmåte for behandling av saltfisk
NO941266D0 (no) Fremgangsmåte for modning av fisk
NO961257D0 (no) Fremgangsmåte for slakting av fisk
DK127193D0 (da) Fremgangsmaade ved biologisk rensning
DK136292D0 (da) Fremgangsmaade ved biologisk rensning
NO993427D0 (no) Produksjonsprosess ved tilvirkning av fisk
NO960404D0 (no) Desinfisering av vann
KR960030038U (ko) 관상어용 수족관의 전자식히터
BR7502005U (pt) Criadouro artificial de custáceo marinho
DK182691D0 (da) Fremgangsmaade ved biologisk rensning
DK256790D0 (da) Fremgangsmaade ved biologisk rensning
UA25843C2 (uk) Спосіб стерилізації води

Legal Events

Date Code Title Description
MK1K Patent expired